STAT+: Vertex kidney disease drug scrutinized for infection risk

This is the online version of Adam’s Biotech Scorecard, a weekly newsletter featuring exclusive, spicy analysis on the biotech industry. Sign up here to get it delivered to your inbox. Spain is amazing. I was in Madrid for five days covering the ESMO conference. Now, I’m delivering this newsletter to you from a balcony overlooking the Mediterranean. Vertex kidney disease drug scrutinized for infection risk ahead of FDA approval decision So many medical meetings, so little time. While I was in Ma...